Quantifying secondary pharmacology antagonistic drug effects on platelet function
The development of new drugs is often limited or even halted by their side effects on platelet function. In drug discovery, identifying compounds that might have secondary pharmacological effects on platelet function can contribute to de-risking and help with the progression of potential new drugs. Half-maximal inhibitory concentration (IC50 or pIC50 (-log10IC50)), the concentration of […]
Anti-platelet therapy: future directions
In our blog series on anti-platelet therapy, we have covered the development of both intravenous and oral therapies and the role of platelet function testing in the discovery, development and monitoring of these agents. In this latest commentary, we speculate on future directions in this area. The future landscape can be divided into two themes: […]
Megakaryoctyes and Platelets in Manchester: Platelet Society Meeting 2025
The Platelet Services team were pleased to sponsor and participate in this year’s meeting of the Platelet Society held in the Dalton Building at Manchester Metropolitan University, from April 23-25. We particularly enjoyed sharing, in a joint poster and flash presentation with Molecular Devices, the progress made in converting platelet function testing to a 96-well […]
Updates from the Society of Toxicology 64th Annual Meeting
The Platelet Services team returned home buoyant from a successful trip to Orlando for the Society of Toxicology 64th Annual Meeting and ToxExpo. It was our first attendance at this conference, and the format worked well for us. The poster sessions were outstanding, sited in multiple sections around the huge exhibition hall with plenty of […]
Platelet Services 2024 Round-up
From working on exciting client projects to attending industry events across the globe, it’s been another super busy but rewarding year here at Platelet Services HQ. In this end of year round-up, we discuss some of the highlights of our year and look ahead at what’s in store for us in 2025. Our technical […]
Platelet function testing – shifting applications
In the latest instalment of our antiplatelet therapy series, we take a look at platelet function testing and how requirements for it have shifted throughout the years. In our previous blogs, we have outlined the evolution of anti-platelet therapy and the pivotal role these therapies have come to play in the management of cardiovascular disease. […]
Eurotox 2024: Toxicology at the Tivoli
At the beginning of September the Platelet Services team were delighted to attend Eurotox 2024, held at the Tivoli Hotel and Congress Centre in Copenhagen. This was the first time the team had attended the event organised by the Danish Society of Toxicology and Pharmacology and it did not disappoint! Eurotox 2024 included a packed […]
Meet the team: Bob Humphries
In the latest instalment of our ‘Meet the Team’ series, we sat down with Bob Humphries, Platelet Services’ Non-Executive Director and Drug Discovery Advisor, to discuss his career journey and what he thinks makes Platelet Services such a special company. Early inspirations Bob has always felt that the field of science and medicine was exciting, […]
Intravenous antiplatelet therapy – for when the going gets tough
In the second instalment of our antiplatelet therapy series, we take a look at intravenous (IV) antiplatelet therapy and how it came to be used. In a previous blog1, we provided a brief overview of the 50-year evolution of oral anti-platelet therapy, which began with the findings of the first randomised, controlled trial of aspirin […]
The importance of platelet testing
While it is not a regulatory requirement to test the effect of all drugs on platelets, platelet testing can be an important stage of the drug discovery process that will help companies understand the possible effects of their compounds in development on platelets and de-risk further development process. The purpose of platelet testing There are […]
